26 MAIN STREET, SUITE 101, CHATHAM, NJ
8-K
Tonix Pharmaceuticals Begins Phase 1 Study of TNX-1900 for Migraine and Pain
Tonix Pharmaceuticals Dismisses EisnerAmper as Independent Auditor
Financial Results, Press Release
Annual Report to Security Holders
Reg. FD, Other Events
Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market
Tonix Pharmaceuticals Reports Preliminary Financial Results for 2025
Q3
Q2
Q1
FY 2024
Notice of Late Filing for Quarterly Report
Prospectus filed pursuant to Rule 424(b)(5)
Amended Registration Statement for Securities Offered under a Shelf Registration
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload